# EDGAR Filing Document

**Accession Number:** 0001660334
**File Stem:** 0001193125-26-164025
**Filing Date:** 2026-4
**Character Count:** 4429
**Document Hash:** 8c2cb853a6335dc34cb156a4b3946c8c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-164025.hdr.sgml**: 20260420

**ACCESSION NUMBER**: 0001193125-26-164025

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260420

**DATE AS OF CHANGE**: 20260420

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Verrica Pharmaceuticals Inc.
- **CENTRAL INDEX KEY:** 0001660334
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 463137900
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38529
- **FILM NUMBER:** 26875228

**BUSINESS ADDRESS:**
- **STREET 1:** 44 WEST GAY STREET
- **STREET 2:** SUITE 400
- **CITY:** WEST CHESTER
- **STATE:** PA
- **BUSINESS PHONE:** 484-453-3300

**MAIL ADDRESS:**
- **STREET 1:** 44 WEST GAY STREET
- **STREET 2:** SUITE 400
- **CITY:** WEST CHESTER
- **STATE:** PA

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**SCHEDULE 14A** 

**Proxy Statement Pursuant to Section 14(a) of the** 

**Securities Exchange Act of 1934** 

Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))** 

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material under § 240.14a-12

## Verrica Pharmaceuticals Inc.
**(Name of Registrant as Specified In Its Charter)** 

**(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)** 

Payment of Filing Fee (Check all boxes that apply)

☒ No fee required

☐ Fee paid previously with preliminary materials

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

------

![LOGO](g28726g01a01.jpg)

Your Vote Counts! VERRICA PHARMACEUTICALS INC. 2026 Annual Meeting Vote by June 4, 2026 11:59 PM ET VERRICA PHARMACEUTICALS INC. 44 W. GAY STREET, SUITE 400 WEST CHESTER, PA 19380 V90640-P50047 You invested in VERRICA PHARMACEUTICALS INC. and it's time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 5, 2026. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 22, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Vote in Person at the Meeting\* Point your camera here and June 5, 2026 10:00 AM EDT vote without entering a control number Company's Headquarters 44 W. Gay St., Suite 400 West Chester, PA 19380 \*Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

------

![LOGO](g28726g01a02.jpg)

Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Board Voting Items Recommends 1. Election of Directors Nominees: For 01) Paul B. Manning 02) Lawrence Eichenfield 2. Approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the For proxy statement. 3. Ratification of the selection by the Audit Committee of KPMG LLP as the independent registered public accounting For firm for the fiscal year ending December 31, 2026. 4. Approval of the Company's Amended and Restated 2018 Equity Incentive Plan. For NOTE: Such other business as may properly come before the meeting, including any adjournment or postponement thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings". V90641-P50047